Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Montserrat-Capdevila J, Godoy P, Marsal JR, Barbe F. Predictive model of hospital admission for COPD exacerbation. Resp Care. 2015 Sep;60(9):1288-94. doi: 10.4187/respcare.04005